methicillin-resistant staphylococcus aureus : a clinical policy
DESCRIPTION
Methicillin-Resistant Staphylococcus aureus : a clinical policy. John M. Howell, MD, FACEP, FAAEM Best Practices, Inc Inova Fairfax Hospital Department of Emergency Medicine June 25 - 27, 2009. Sometimes MRSA can be intimidating. Even a little scary. But we can usually get what we want. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/1.jpg)
Methicillin-Resistant Staphylococcus aureus: a clinical
policy
John M. Howell, MD, FACEP, FAAEMBest Practices, Inc
Inova Fairfax HospitalDepartment of Emergency Medicine
June 25 - 27, 2009
![Page 2: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/2.jpg)
Sometimes MRSA can be intimidating
![Page 3: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/3.jpg)
Even a little scary
![Page 4: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/4.jpg)
But we can usually get what we want
![Page 5: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/5.jpg)
Let’s start with two cases that will lead up to our clinical question.
![Page 6: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/6.jpg)
8 year old boy with ankle pain
• Twisted his ankle playing basketball 6 days prior
• Lateral ankle swelling
• Xray negative
• Discharged with ankle sprain
![Page 7: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/7.jpg)
Returns to the ED 3 days later
• Temperature 102oF• Tachycardic• Lower leg swollen from the knee to the foot,
brawny-red appearance• Warm and tender lower leg• WBC 9,800/mm3
• CRP - 45
![Page 8: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/8.jpg)
And the MRI shows …
![Page 9: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/9.jpg)
![Page 10: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/10.jpg)
In retrospect, there was no history of skin lesion or trauma, although the child did play basketball frequently.
![Page 11: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/11.jpg)
Seven Year Old Male with Cough and Fever
• 3 days of cough, fever, and “abd pain”
• Decreased intake
• PMH: ED visit 1/12/08, left hip abscess, grew MRSA, treated with clindamycin
• BP 104/55; P 118/min, RR 20/min, T 99.7, pulse ox 95% on RA
![Page 12: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/12.jpg)
Seven Year Old with Cough and Fever: Physical Exam
• WD/WN, alert and laying quietly• HEENT: Normal• Resp: Tachypnea, nasal flaring, rales L lung• CV: Tachycardic• Abd: Soft, diffusely tender without guarding.
Normal BSs• Skin: No rash• Neuro: Non-focal examination
![Page 13: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/13.jpg)
Seven Year Old with Cough and Fever: Diagnostic Studies
• WBC: 20,000, 81S, 12L, 6M, 1E
• H/H 10.5/32; Plat 382
• Chemistry: K 3.0
• Flu Swab: Negative
![Page 14: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/14.jpg)
![Page 15: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/15.jpg)
Seven Year Old with Cough and Fever: Clinical Course
• In ED, child became more SOB• pulse ox dropped to 92%.• Given IV fluids, Rocephin, Clindamycin• Admitted to IFH PICU• Remained 12 days. Blood cultures: MRSA• Chest CT – pulmonary consolidation with
pleural effusion
![Page 16: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/16.jpg)
MRSA Overview
• Nosocomial MRSA has been around since the 1960’s.
• Community acquired MRSA became a problem in the 1990’s.
• Although CA MRSA is more virulent, it is usually sensitive to more antimicrobials.
![Page 17: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/17.jpg)
MRSA Virulence Factors
• Type IV SCC mec - mechanism for antimicrobial resistance
• Panton Valentine Leukocidin (PVL) – Pokes holes in leukocytes– More prominent in CA MRSA– Associated with pneumonia and severe
skin infections
![Page 18: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/18.jpg)
MRSA Community Acquired Pneumonia
• Jan 2007 – 10 cases of MRSA CAP in healthy kids during flu season: 6 deaths
• Association with flu was either by lab test or clinical presentation
• All MRSA isolates positive for PVL• All had 3-4 day interval between presentation and
severe illness or death• 4/10 had documented MRSA in themselves or
contacts
![Page 19: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/19.jpg)
So if we know that MRSA has varying levels of antimicrobial resistance and, via PVL, can cause severe disease …
![Page 20: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/20.jpg)
Clinical Question
Should skin abscesses be treated routinely by I and D followed by a course of oral antibiotics that cover MRSA?
![Page 21: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/21.jpg)
Following I and D of a skin abscess, I …
A. Do not routinely prescribe oral antibiotics
B. Routinely prescribe oral antibiotics that cover MRSA
C. Routinely prescribe oral antibiotics that cover MSSA (e.g., cephalexin)
D. Routinely prescribe oral antibiotics only for pateints with immune compromise
![Page 22: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/22.jpg)
Let’s look at the literature
![Page 23: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/23.jpg)
Rajendran et al, J Am Coll Surg, 2006
• Prospective placebo controlled trial of cephalexin following I and D
• 50% MRSA incidence• High prevalence of HIV and other immune
issues• In the MRSA subgroup (about 50 subjects),
the rates of abscess recurrence were 88% and 89% for cephalexin vs. placebo.
![Page 24: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/24.jpg)
Lee et al, Pediatr Infect Dis, 2004
• Prospective observational study of 67 children with MRSA skin abscesses
• 5 treated with appropriate antibiotics, 62 with “discordant” antibiotics
• At follow up, all 5 with appropriate therapy improved, but 58 of 62 (94%) in discordant group improved. Most who did not improve were admitted.
![Page 25: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/25.jpg)
Moran et al, NEJM, 2006
• Prospective cohort of patients with abscesses in an ED
• 78% of staph isolates were MRSA• About 400 subjects, but 40% dropped out or
were excluded• No difference in recurrence rates for
concordant and discordant antibiotics• Treatment not standardized and many
subjects either not included or lost to follow up
![Page 26: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/26.jpg)
Paydar et al, Arch Surg, 2006
• Restrospective cohort of 280 patients with MRSA abscesses
• When corrected for intention to treat, 99% cure rate for concordant therapy, and 92% cure rate for discordant antimicrobial treatment.
![Page 27: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/27.jpg)
Clinical Policy
• Guidelines (2008) for the prophylaxis and treatment of MRSA infections in the United Kingdom
• Journal of Antimicrobial Chemotherapy• Antibiotic therapy is not generally
required after the I and D of small (< 5 cm) abscesses without surrounding cellulitis.
![Page 28: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/28.jpg)
Clinical Policy
• This clinical policy bases it’s recommendation on one reference, Rajendran.
• Prospective cohort of about 50 MRSA abscesses treated with cephalexin or placebo, which found no difference in recurrence rates
![Page 29: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/29.jpg)
I don’t know about you, but this can all be a lot to take in …
![Page 30: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/30.jpg)
![Page 31: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/31.jpg)
And so, knowing that:
• MRSA isolates occur frequently
• A small number of patients with MRSA skin infections may develop serious pneumonia, necrotizing fasciitis, and osteomyelitis
• The literature is what it is
![Page 32: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/32.jpg)
Where is your acceptable level of risk?
• Given the risk of distant infection, how many times out of one hundred are you willing to under treat a MRSA skin infection?
• 1, 2, 5, 10 … ???
![Page 33: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/33.jpg)
Our final step is to write a management recommendation for our clinical policy on the treatment of cutaneous abscesses.
![Page 34: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/34.jpg)
Pick one of the following clinical policy recommendations:
A. Routinely prescribe oral antibiotics that cover MRSA following I and D of cutaneous abscesses.
B. Routinely prescribe oral antibiotics that cover MSSA following I and D of cutaneous abscesses.
C. No not routinely prescribe oral antibiotics following I and D of cutaneous abscesses.
D. Prescribe oral antibiotics that cover MRSA, following I and D of cutaneous abscesses, only for patients with immune competency issues (e.g., HIV, DM, PVD).
![Page 35: Methicillin-Resistant Staphylococcus aureus : a clinical policy](https://reader033.vdocuments.us/reader033/viewer/2022061617/5681598b550346895dc6cfef/html5/thumbnails/35.jpg)
If I did choose to treat, I would prescribe:
• Clindamycin
• Doxycycline
• Trimethoprim/Sulfamethoxasole
• Cepahlexin
• Augmentin